LEXINGTON, Mass., Sept. 10, 2020 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that James Dentzer,
President and Chief Executive Officer of Curis, will provide a
company overview at two upcoming investor conferences:
- Cantor Fitzgerald Virtual Global Healthcare Conference:
Fireside Chat – Tuesday, September 15,
2020 at 9:20 am ET.
- H.C. Wainwright & Co. 22nd Annual Global Investment
Conference: Tuesday, September 15,
2020 at 4:30 pm ET.
A live webcast of each presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website at www.curis.com. A replay of the webcast will be
available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including, the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with non-Hodgkin
lymphoma and in a Phase 1 trial in patients with acute myeloid
leukemia and myelodysplastic syndromes. In addition, Curis is
engaged in a collaboration with ImmuNext for development of
CI-8993, a monoclonal anti-VISTA antibody, which is planned to
be tested in a Phase 1a/1b trial in patients with solid
tumors. Curis is also party to a collaboration with Genentech, a
member of the Roche Group, under which Genentech and Roche are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis' website
at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-investor-conferences-301127921.html
SOURCE Curis, Inc.